Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BGE 117

Drug Profile

BGE 117

Alternative Names: BGE-117; TS-143

Latest Information Update: 23 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Taisho Pharmaceutical
  • Developer BioAge Labs; Taisho Pharmaceutical
  • Class Small molecules
  • Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Anaemia
  • Discontinued Renal failure

Most Recent Events

  • 05 May 2022 BioAge Labs withdraws a phase II clinical trial for Anaemia (In the elderly) in Australia prior to enrolment, as of May 2022 (PO) (NCT05152641)
  • 01 May 2022 Phase-II clinical trials in Anaemia (In the elderly) in Australia (PO) (BioAge Labs pipeline, May 2022)
  • 01 Apr 2022 BioAge Labs withdraws a phase II clinical trial in Anaemia (In the elderly) in Australia prior to enrolment, in April 2022 (PO) (NCT04815603)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top